{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:48:49Z","timestamp":1788608929266,"version":"build-2803163510"},"reference-count":94,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Alogliptin, a dipeptidyl peptidase\u20104 (<jats:styled-content style=\"fixed-case\">DPP<\/jats:styled-content>\u20104) inhibitor that is a class of relatively new oral hypoglycaemic drugs used in patients with type 2 diabetes (T2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>), can be used as monotherapy or in combination with other anti\u2010diabetic agents, including metformin, pioglitazone, sulfonylureas and insulin with a considerable therapeutic effect. Alogliptin exhibits favorable pharmacokinetic and pharmacodynamic profiles in humans. Alogliptin is mainly metabolized by cytochrome P450 (<jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2D6) and <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>3A4. Dose reduction is recommended for patients with moderate or worse renal impairment. Side effects of alogliptin include nasopharyngitis, upper\u2010respiratory tract infections and headache. Hypoglycaemia is seen in about 1.5% of the T2<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> patients. Rare but severe adverse reactions such as acute pancreatitis, serious hypersensitivity including anaphylaxis, angioedema and severe cutaneous reactions such as Stevens\u2010Johnson syndrome have been reported from post\u2010marketing monitoring. Pharmacokinetic interactions have not been observed between alogliptin and other drugs including glyburide, metformin, pioglitazone, insulin and warfarin. The present review aimed to update the clinical information on pharmacodynamics, pharmacokinetics, adverse effects and drug interactions, and to discuss the future directions of alogliptin.<\/jats:p>","DOI":"10.1111\/1440-1681.12469","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T14:18:54Z","timestamp":1438093134000},"page":"1225-1238","source":"Crossref","is-referenced-by-count":19,"title":["An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus"],"prefix":"10.1111","volume":"42","author":[{"given":"Xiao\u2010Wu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of General Surgery The First People's Hospital of Shunde Southern Medical University Shunde Foshan Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi\u2010Xu","family":"He","sequence":"additional","affiliation":[{"name":"Guizhou Provincial Key Laboratory for Regenerative Medicine Stem Cell and Tissue Engineering Research Center &amp; Sino\u2010US Joint Laboratory for Medical Sciences Guiyang Medical University Guiyang Guizhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi\u2010Wei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy University of South Florida Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University of Utah and Salt Lake Veterans Affairs Medical Center Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueji","family":"Zhang","sequence":"additional","affiliation":[{"name":"Research Center for Bioengineering and Sensing Technology University of Science and Technology Beijing Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin\u2010Xue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery General Hospital of Ningxia Medical University Yinchuan Ningxia China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Duan","sequence":"additional","affiliation":[{"name":"School of Medicine Deakin University Waurn Ponds Vic. Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu\u2010Feng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Guizhou Provincial Key Laboratory for Regenerative Medicine Stem Cell and Tissue Engineering Research Center &amp; Sino\u2010US Joint Laboratory for Medical Sciences Guiyang Medical University Guiyang Guizhou China"},{"name":"Department of Pharmaceutical Sciences College of Pharmacy University of South Florida Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62219-9"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.726"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1103643"},{"key":"e_1_2_8_5_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2013"},{"key":"e_1_2_8_6_1","volume-title":"National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70144-5"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.243"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60472-8"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70175-X"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60283-9"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60207-9"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1005073"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60614-4"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70065-0"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60613-9"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.09.007"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565030-00005"},{"key":"e_1_2_8_19_1","first-page":"1345","article-title":"Novel serine protease dipeptidyl peptidase IV inhibitor: Alogliptin","volume":"12","author":"Agrawal R","year":"2012","journal-title":"Mini Rev. Med. Chem."},{"key":"e_1_2_8_20_1","first-page":"989","article-title":"Dipeptidyl peptidase\u20104 inhibitors in type 2 diabetes therapy \u2010 focus on alogliptin","volume":"7","author":"Capuano A","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm070104l"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013504076"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130131"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4807-580"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190014522063"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.898750"},{"key":"e_1_2_8_27_1","first-page":"186","article-title":"Alogliptin (nesina) for adults with type\u20102 diabetes","volume":"39","author":"Dineen L","year":"2014","journal-title":"P T"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871529X14666140701095849"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/07435800.2014.952743"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.944862"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1385\/CBB:44:3:349"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-006-6317-y"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920308783565723"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0098.edw"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-0407.2011.00143.x"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-0115(99)00089-0"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.120069197"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0631828100"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-1809.1990.tb00377.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1016\/S0021-9258(18)42906-7","article-title":"Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte\u2010like colon cancer cell lines HT\u201029 and Caco\u20102. Cloning of the complete Hum.an coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation","volume":"267","author":"Darmoul D","year":"1992","journal-title":"J. Biol. Chem."},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4049\/jimmunol.149.2.481","article-title":"Cloning and functional expression of the T cell activation antigen CD26","volume":"149","author":"Tanaka T","year":"1992","journal-title":"J. Immunol."},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4781(92)90036-Y"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01246674"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.111.2.323"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.09.012"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605236"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1042\/0264-6021:3610203"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsb882"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101016w"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.11.008"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1296"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07952-7"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2014.50.4.2132740"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.9.896"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152512803530379"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-13-0195"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.838559"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-012-9729-9"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/prot.21138"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.10.2988"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01933.x"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01463.x"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12258"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0159"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903156111"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2243"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0639"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12377"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12102"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.01016.x"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.614936"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ13-0466"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12059"},{"key":"e_1_2_8_75_1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1507\/endocrj.EJ12-0290","article-title":"Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin","volume":"60","author":"Kusunoki Y","year":"2013","journal-title":"Endocrine J."},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01124.x"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.956722"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.03.004"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1035"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.599371"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01156.x"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2009.02484.x"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261927"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.03.005"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01212.x"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.2165\/11532980-000000000-00000"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12295"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.2165\/11591400-000000000-00000"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009338938"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12176"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2366"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0171-x"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12093"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP48046"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1440-1681.12469","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.12469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:46:51Z","timestamp":1696366011000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1440-1681.12469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":94,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1111\/1440-1681.12469"],"URL":"https:\/\/doi.org\/10.1111\/1440-1681.12469","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]}}}